Gut-enriched KruÈ ppel-like factor (GKLF or KLF4) is a zinc ®nger-containing, epithelial-speci®c transcription factor, that functions as a suppressor of cell proliferation. We previously showed that GKLF expression is decreased in intestinal and colonic adenomas, respectively, from multiple intestinal neoplasia (Min) mice and familial adenomatous polyposis (FAP) patients. This study shows that GKLF is induced upon activation of the adenomatous polyposis coli (APC) gene. However, among several human colon cancer cell lines surveyed, expression of GKLF is lowest in RKO, a line with wildtype APC and b-catenin. RKO contains a mutated allele that encodes the putative tumor suppressor homeodomain protein, CDX2. We show that wild-type CDX2 activates the GKLF promoter and that the mutated CDX2 has a dominant negative eect on wild-type function. Our results may help explain the exceedingly low levels of GKLF expression detected in this cell line, which may in turn contribute to the tumor phenotype. Oncogene (2001) 20, 4884 ± 4890.
The mammalian gut epithelium is a dynamic system in which cell proliferation is coupled to dierentiation, and aberrations in this process frequently lead to colon cancer. Mutations of the tumor suppressor gene adenomatous polyposis coli (APC) have been shown to initiate neoplastic transformation in colorectal cancers Nishisho et al., 1991; Groden et al., 1991; Joslyn et al., 1991) . The importance of APC is demonstrated by the ®nding that both of its alleles are mutated in greater than 85% of familial and sporadic colorectal tumors (Ichii et al., 1992) . APC is a cytoplasmic protein that modulates the oncogenic Wnt signal transduction cascade by binding to b-catenin and promoting its phosphorylation by glycogen synthase kinase 3b (GSK3b), for subsequent degradation (Polakis, 2000) . When APC is mutated, bcatenin accumulates, translocates into the nucleus, and binds to the transcription factor T-cell factor 4 (Tcf4) Korinek et al., 1997) . The bcatenin/Tcf4 complex activates target genes that promote cell growth such as c-MYC, cyclin D1, and PPAR-d (He et al., 1998; Tetsu and McCormick, 1999; He et al., 1999) .
The gut-enriched KruÈ ppel-like factor (GKLF, also known as KruÈ ppel-like factor 4 or KLF4) is a recently identi®ed zinc ®nger transcription factor (Shields et al., 1996) , and a member of the larger mammalian KLF family (Dang et al., 2000a) . Several lines of evidence indicate that GKLF is an important regulator of cell proliferation. In mice, GKLF transcripts start to rise on embryonic day 13 and peak at embryonic day 17, correlating with a critical period of gut epithelium morphogenesis (Ton-That et al., 1997) . In vivo, GKLF is highly expressed in the post-mitotic, terminally dierentiated epithelial cells of the intestine (Shields et al., 1996) and the skin (Garrett-Sinha et al., 1996; Segre et al., 1999) . In cultured cells, expression of GKLF is temporally associated with conditions that promote growth arrest such as serum deprivation, contact inhibition, and DNA damage (Shields et al., 1996; Zhang et al., 2000) ; and constitutive production of GKLF results in the inhibition of DNA synthesis (Shields et al., 1996) . In mice de®cient of GKLF, latestage dierentiation of the epidermis is disturbed and they die shortly after birth due to inability to maintain a skin barrier (Segre et al., 1999) . GKLF activates the promoter of the cyclin-dependent kinase inhibitor p21 WAF1/Cip1 gene in a p53-dependent manner (Zhang et al., 2000) , represses the cyclin D1 promoter (Shie et al., 2000a) , and induces cell cycle arrest at the G1/S boundary (Shie et al., 2000b) .
We recently reported that expression of GKLF is decreased in intestinal adenomas of multiple intestinal neoplasia (Min) mice and in colonic adenomas of familial adenomatous polyposis (FAP) patients (Dang et al., 2000b) , both of which inherit a germline mutation of APC and form tumors when the second allele somatically mutates (Moser et al., 1990; Ichii et al., 1992) . In Min mice, the level of GKLF transcript is highest in normal-appearing intestinal tissue and decreases as the size of the adenoma increases. A similar decrease is also noted in colonic adenomas of FAP patients. In addition, an independent group has recently reported similar decreases in GKLF in sporadic colorectal adenomas and carcinomas (Shie et al., 2000b) . The mechanisms for the decreased expression of GKLF in tumors are presently unknown. However, since adenomas of Min mice and FAP patients arise from a loss of APC function and these adenomas have decreased GKLF expression, we hypothesized that GKLF expression may be regulated by APC.
In the present study, we demonstrate that activation of APC can indeed induce GKLF expression. We pursued potential mechanisms by which APC induces GKLF expression, using colon cancer cell lines with varying APC and b-catenin mutations. Unexpectedly, we found that GKLF expression is particularly decreased in the human colon cancer cell line RKO, which paradoxically has both wild-type APC and bcatenin (Da Costa et al., 1999) . However, RKO cells have one mutated allele of CDX2 (Da Costa et al., 1999) . CDX2 is a member of the caudal-related homeobox gene family, with sequence homology to the caudal gene of Drosophila melanogaster (Duprey et al., 1988) . CDX2 is speci®cally expressed in the intestine and is important for regulation of intestinal epithelial cell development and maintenance. In mice, Cdx2 expression begins on embryonic day 9.5, speci®cally in the dierentiated villi of the distal small bowel and proximal colon (Silberg et al., 2000) . Forced expression of Cdx2 in the rat intestinal epithelial cell line IEC-6 delayed cell growth and induced cellular dierentiation as characterized by the appearance of columnar epithelium with tight junctions, microvilli formation, and lateral membrane interdigitations (Suh and Traber, 1996) . Moreover, the dierentiated cells expressed sucrase-isomaltase (SI) and lactase-phlorizin hydrolase (LPH), which are molecular markers of dierentiated enterocytes. Indeed, Cdx2 binds to cis-elements present in the promoters of both SI and LPH (Suh et al., 1994; Fang et al., 2000) . While Cdx2 null mice die in utero before implantation, heterozygous null Cdx2 mice develop colonic tumors in addition to various skeletal defects (Chawengsaksophak et al., 1997) . Cdx2 may therefore play a role in the pathogenesis of colorectal tumor formation. In a large percentage of colorectal tumors, CDX2 mRNA and protein are decreased (Mallo et al., 1997; Ee et al., 1995) . Forced expression of CDX2 in the colorectal cancer cell line Caco2 increased expression of genes involved with matrixmediated dierentiation such as SI, E-cadherin, APC, b-4, HD1, and laminan 5 Duluc et al., 1997) . Similarly, over-expression of CDX2 in HT29 colorectal cancer cells decreased cell proliferation, migration, and tumor growth in nude mice (Mallo et al., 1998) . We now show that wild-type but not mutant CDX2 transactivates the GKLF promoter in RKO cells. Moreover, the mutated CDX2 behaves in a dominant negative fashion to inhibit transactivation of the GKLF promoter by wildtype CDX2. The results of our study, coupled with the ®nding that APC induces CDX2 expression (Da Costa et al., 1999) , suggest that these proteins may form a particular tumor suppressor pathway in the sequence of APC?CDX2?GKLF and that the resultant negligible expression of GKLF may contribute to the tumor phenotype in RKO cells.
Induction of GKLF expression by APC
To determine whether expression of GKLF is aected by APC, we induced APC expression in HT29-APC cells and measured the levels of GKLF transcripts by Northern blot analysis after various periods of induction. HT29 human colon cancer cells carry truncating mutations of both APC alleles. When wild-type APC expression is re-established in these cells, growth inhibition and apoptosis results (Morin et al., 1996) . Figure 1 shows that GKLF message content is increased at 4 and 8 h after APC induction (Panel A). In contrast, this increase is negligible in the control HT29-b-Gal cells after the same periods of induction (Panel B). The increase in the level of GKLF transcript in HT29-APC but not HT29-b-Gal cells is apparent after standardizing for the control GAPDH message content (Panel C).
Quanti®cation of GKLF mRNA levels and promoter activities in colon cancer cell lines
To identify the mechanism by which APC induces GKLF expression, we performed RT ± PCR and Northern blot analysis for GKLF transcripts in ®ve dierent human colon cancer cell lines: Caco2, RKO, HCT116, SW480, and HT29. All of these cell lines, except for RKO, have a mutation in either APC or b-catenin, both of which result in constitutive b-catenin/TCF regulated transcription (Da Costa et al., 1999) . It was therefore quite surprising that the level of GKLF transcripts was nearly undetectable in RKO cells relative to the others, as measured by both RT ± PCR and Northern blot analysis (Figure 2a, b) . This result appears to contrast with the notion that GKLF is regulated by APC as suggested by the ®nding in Figure 1 .
To evaluate whether the decreased expression of GKLF in RKO cells was due to an alteration in transcription, we transfected the ®ve colon cancer cell lines and one hepatoma cell line, HepG2, with a reporter containing the 1 kb 5'-¯anking promoter region of GKLF linked to the ®re¯y luciferase reporter. As expected, HepG2 has very low GKLF promoter activity ( Figure 2c ) and mRNA levels (data not shown); consistent with our previous ®ndings that GKLF is not expressed in the liver (Shields et al., 1996) .
When compared to the other colon cancer cell lines, we ®nd that GKLF promoter activity is signi®cantly lower (P50.05) in RKO cells (Figure 2c ). This suggests that the low level of GKLF transcripts in RKO cells is due to decreased transcription in this cell line. (Morin et al., 1996) . Upon induction with ZnCl 2 , APC protein is rapidly synthesized and reaches maximal levels by 9 h (He et al., 1998) . Cells were cultured in McCoy's 5A supplemented with 10% fetal bovine serum (FBS) and 0.6 mg/ml hygromycin. APC or b-Gal expression was induced by the addition of 100 mM ZnCl 2 . Total RNA was isolated from cells by the TRIzol method (Life Technologies, Inc, Gaithersburg, MD, USA). Northern blot analysis was performed as previously described (Shields et al., 1996) . Hybridisations and washings were performed under high-stringency conditions using a radioactively labelled 1.6 kb full-length human GKLF cDNA probe (Jenkins et al., 1998) . To control for loading of RNA samples, blots were simultaneously probed with radioactively labeled full-length human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNA (Clontech, Palo Alto, CA, USA). The ratio of GKLF message to GAPDH message was calculated by dividing the densitometric measurement of the intensity for each GKLF band with that for the corresponding GAPDH band, using a value of 1.0 at time 0 for each cell line Fifteen mg of total RNA were extracted from the above colon cancer cell lines and probed for GKLF and GAPDH by Northern blot as described in Figure 1 . The status of APC and b-catenin in each cell line is shown (+, wild-type; 7, mutant) . Note that the mutation in b-catenin results in constitutive activation of the protein . (c) GKLF promoter activity in various cell lines. Cells were transfected with 5 mg of 71.0 kb GKLF ± pGL2-luciferase and 2 mg CMV-renilla luciferase by lipofection. Fire¯y and Renilla luciferase assays were determined 24 h after transfection. The fold induction was calculated by comparing the activity of the GKLF-Luciferase reporter to that of pGL2 vector alone after standardizing with the internal control renilla luciferase activity. Shown are means of four independent experiments. Bars represent standard deviations. *P50.05 compared to Caco2, HCT116, SW480, or HT29. Caco2, RKO, HCT116, SW480, and HT29, were cultured in DMEM (®rst two cell lines) or McCoy's 5A (latter three cell lines) with 10% FBS and 100 units/ml penicillin and 100 mg/ml streptomycin. For RT ± PCR, 5 mg of total RNA was treated with ampli®cation-grade DNase I per protocol (Life Technologies, Inc.
[LTI], Gaithersburg, MD, USA). One hundred twenty-®ve ng DNase Itreated RNA was subject to RT ± PCR using primers for human GKLF with b-actin as a control for loading as previously described (Dang et al., 2000b) . Transient transfection of 40 ± 50% con¯uent RKO, Caco2, HCT116, SW480, HT29, and HepG2 cells with the 71.0 kb GKLF ± pGL2-Luciferase reporter construct containing 1 kb of the 5'-¯anking GKLF promoter (Mahatan et al., 1999) was performed in triplicate using the Lipofectamine reagent protocol (LTI). All transfections included the internal standard CMV-Renilla Luciferase to normalize for transfection eciency. Fire¯y and renilla luciferase assays were performed in triplicate as described in the Dual-luciferase kit protocol (Promega, Madison, WI)
The eects of wild-type and mutant CDX2 on GKLF, CDX2, SI, and TCF3 promoters in RKO cells RKO cells have been shown to have one mutated allele of CDX2 that results in a frame shift in the C terminal portion of the protein (Da Costa et al., 1999) . We previously showed that there is a CDX2-binding site in the GKLF promoter beginning at nucleotide position 7907 from the start-site of transcription and that CDX2 transactivates 1.0 kb of the GKLF promoter (Mahatan et al., 1999) . It is therefore possible that the low level of GKLF expression in RKO cells is due to a haploinsuciency of CDX2. To test whether wild-type CDX2 can restore GKLF promoter activity in RKO cells, we co-transfected CMV-wild-type CDX2 or CMV-mutant CDX2 with the 71.0 kb GKLF ± pGL2-luciferase reporter into RKO cells. Figure 3a shows that wild-type but not mutant CDX2 transactivates the GKLF promoter. In addition, we ®nd that the promoters of two known CDX2-responsive genes, SI (Suh and Traber, 1996) and CDX2 (Da Costa et al., 1999) , are also transactivated by wild-type CDX2 but not mutant CDX2 (Figure 3a) . In contrast, the TCF3-wild-type (WT) promoter, which does not have a CDX2-binding site, is not transactivated by wild-type or mutant CDX2. These ®ndings indicate that the mutation in CDX2 results in a loss of its protein's ability to activate the GKLF promoter.
Mutant CDX2 inhibits activation of the GKLF promoter by wild-type CDX2
In addition to the possibility that haploinsuciency of CDX2 results in decreased GKLF expression, the mutant CDX2 may exert a dominant negative eect on wild-type function in RKO cells. To test the latter hypothesis, we performed competition studies, cotransfecting RKO cells with the GKLF ± luciferase reporter and increasing ratios of mutant over wildtype CDX2. We ®nd that as the amount of mutant CDX2 increases, the ability of wild-type CDX2 to transactivate the GKLF promoter decreases ( Figure  3b ). These ®ndings suggest that the mutation in CDX2 present in RKO cells may confer a dominant negative activity over the wild-type protein.
The eects of constitutively active b-catenin on the GKLF, CDX2, SI, and TCF3 promoters in RKO cells
One mechanism by which APC functions is to downregulate b-catenin ± Tcf-regulated transcription (CRT) . When APC is mutated, CRT increases and downstream genes such as c-MYC and cyclin D1 are over-expressed. Some colorectal tumors have intact APC but constitutively activating mutations of b-catenin that lead to an increase in CRT . Neither of the CDX2 or GKLF promoters has a Tcf4-binding site, and is thus less likely to be under CRT regulation. This was con®rmed by co-transfections in RKO cells with a constitutively active mutant b-catenin (S33Y) and various luciferase reporters. As expected, the S33Y-b-catenin signi®cantly Figure 3 (a) The eect of CDX2 on the GKLF, CDX2, and sucrase-isomaltase (SI) promoters in RKO cells. Five mg/10-cm dish each of pBluescript (pBS), CMV-wild-type CDX2, or CMVmutant-CDX2 were cotransfected with the GKLF-, CDX2-, SI-, or wild-type TCF3-Luciferase reporters. Luciferase activities were determined 24 h after transfection. Fold induction represents the ratio between the luciferase activities in transfected cells over that of pBS co-transfected cells. Wild-type CDX2 signi®cantly (*P50.05) transactivated the GKLF, CDX2, and SI promoters compared to pBS and mutant-CDX2 transfected cells. (b) The eect of mutant CDX2 on the ability of wild-type CDX2 to transactivate the GKLF promoter in RKO cells. Cells were cotransfected with GKLF-Luciferase, pBS, and either wild-type CDX2 alone, wild-type CDX2 with increasing amounts of mutant CDX2, or mutant CDX2 alone. The total amount of DNA transfected was kept constant at 25 mg by the addition of pBS DNA. Fold induction is calculated by dividing the luciferase activity in CDX2-transfected cells over that of pBS-transfected cells. CMV-wild-type CDX2, CMV-mutant CDX2, SI (sucraseisomaltase)-pGL3-Luciferase and TCF3-wild-type (WT)-pGL3-Luciferase were previously described (Da Costa et al., 1999; Korinek et al., 1997) . The CDX2-pGL2-Luciferase reporter was constructed by subcloning a 1 kb Bam/HindIII fragment of the 5'-anking sequence of the mouse CDX2 gene from a 4 kb genomic clone of CDX2 (James et al., 1994) into the pGL2-Luciferase construct through the BglII/HindIII sites. CMV-mutant CDX2 contains the entire coding region of mutant CDX2 cDNA from RKO cells, which has a 4 base-pair deletion (AGGCAGG to AGG) corresponding to helix 3 of the CDX2 homeodomain (Da Costa et al., 1999) . All transfections were performed in triplicate using the Lipofectamine reagent protocol (LTI) on 40 ± 50% con¯uent RKO cells and included the internal standard CMVRenilla Luciferase to normalize for transfection eciency (P50.05) transactivates the wild-type TCF3 promoter but not the mutant TCF3 promoter (Figure 4a) . Importantly, none of the three CDX2-responsive promoters, GKLF, CDX2, and SI, are activated by the constitutively active S33Y-b-catenin (Figure 4a ). These ®ndings suggest that induction of CDX2 and GKLF by APC may occur through a b-cateninindependent pathway.
In summary, the present study establishes GKLF as a downstream target of the APC pathway, thus implicating a potential role for GKLF in mediating not only intestinal growth and dierentiation, but also tumor initiation. Our results show that APC induces GKLF expression. This induction appears to be dependent on the ability of a functional CDX2 to transactivate the GKLF promoter. CDX2, in turn, is activated by APC. We therefore propose that these three proteins form a part of an enterocyte-speci®c tumor suppressor pathway in the sequence of APC?CDX2?GKLF?growth arrest (Figure 4b ). In this paradigm, GKLF plays a`workhorse' role to thè middle manager' CDX2 and`gatekeeper' APC. This pathway is likely to become active as epithelial cells migrate up the intestinal villus and undergo dierentiation with simultaneous loss of proliferative potential. Interestingly, proteins with opposing functions to CDX2 and GKLF have been described. CDX1 and IKLF (intestinal-enriched KruÈ ppel-like factor, or KruÈ ppel-like Factor 5) are primarily expressed in the proliferating compartments of the intestinal crypts and may have reciprocal roles to CDX2 and GKLF in regulating gene transcription and cell proliferation, respectively (Silberg et al., 2000; Conkright et al., 1999; Adam et al., 2000; Sun et al., 2001 ). Moreover, Wnt, which is the product of a proto-oncogene with opposing eects to APC in regards to b-catenin regulation, can up-regulate Cdx1 but not Cdx2 expression (Lickert et al., 2000) . Taken together, these proteins may form an interactive network to regulate intestinal epithelial proliferation and dierentiation along the crypt ± villus axis; and thus aberrations in these proteins may contribute to tumorigenesis.
Whether the induction of CDX2 and subsequently GKLF by APC occurs via b-catenin/TCF-regulated transcription is not known at this time. Three lines of evidence argue against this possibility. First, while APC decreases c-MYC, cyclin D1, and PPARd expression through b-catenin/TCF-regulated transcription, it instead increases CDX2 and GKLF expression. Second, while a recent report found that Wnt/b-catenin/Tcf4 up-regulates Cdx1 expression, it did not ®nd similar changes in Cdx2 expression (Lickert et al., 2000) . Third, our ®nding that the constitutively active bcatenin mutant fails to transactivate either the GKLF or CDX2 promoters suggests that APC may induce CDX2 by a b-catenin-independent pathway. Alternatively, the b-catenin-dependent cis-element in CDX2 may be present elsewhere in the gene. The mechanism of CDX2 induction by APC is potentially important because CDX2 is expressed speci®cally in the gut epithelium and may help explain why APC's gatekeeper function is evident mainly in the gut despite its ubiquitous tissue expression.
The ®nding that mutant CDX2 exhibits a dominant negative eect suggests a potential mechanism by which a CDX2 mutation can contribute to neoplastic growth. CDX2 is a homeodomain protein, which contains three a helixes at the C-terminal in the form Figure 4 (a) The eects of constitutively activated b-catenin mutant (S33Y) on the GKLF, CDX2, SI, and TCF3 promoters in RKO cells. Cells were co-transfected with 5 mg/10-cm dish GKLF ± pGL2-Luciferase, CDX2 ± pGL2-Luciferase, SI ± pGL3-Luciferase, TCF3WT ± pGL3-Luciferase, or TCF3 MutantpGL3-Luciferase, 5 mg CMV ± S33Y-b-catenin, and 2 mg CMVRenilla luciferase by lipofection. Fire¯y and renilla luciferase assays were determined 24 h after transfection. Fold induction represents the ratio of luciferase activity in cells transfected with the S33Y-b-catenin construct over that of pGL2-or pGL3-luciferase. *P50.05 when compared to all other reporters. The wild-type TCF3 reporter has an optimized TCF-binding site upstream of a minimal c-Fos promoter driving luciferase expression; whereas the mutant TCF3 reporter contains a mutated site that does not bind TCF . The eukaryotic expression construct CMV-mutant b-catenin (S33Y) contains the entire mutant b-catenin coding region from SW48 cells, which has a C-to-A missense mutation, changing Ser 33 to Tyr . The resulting mutant b-catenin protein is insensitive to phosphorylation by GSK-3b, rendering it a dominant negative, constitutively active protein. The internal control for transfection was CMV-Renilla Luciferase (Life Technologies, Inc. (LTI), Gaithersburg, MD, USA). All transfections were performed in triplicate using the Lipofectamine reagent protocol (LTI) on 40 ± 50% con¯uent RKO cells and included the internal standard CMV-Renilla Luciferase to normalize for transfection eciency. (b) Model of a proposed APC?CDX2?GKLF pathway of tumor suppression: APC activation increases the level of CDX2 transcripts. CDX2 binds to and activates the GKLF promoter. The dominant negative CDX2 mutant interferes with wild-type CDX2 transactivation of the GKLF promoter, thus abrogating the ability of GKLF to suppress cell proliferation of a helix ± turn ± helix conformation. Helix 3 binds to the major groove of DNA, helix 1 and 2 lie above the DNA, and the N-terminal arm contacts bases in the minor groove (Gehring et al., 1994) . Co-factors bind to homeodomain proteins and confer speci®city in DNA activator or repressor function. The CDX2 mutant allele in RKO cells has a four base pair deletion within the sequence corresponding to helix 3 (Da Costa et al., 1999) . The mutated protein lacks the carboxyl-terminal 85 amino acids; which are substituted with 45 new residues. Since this mutation occurs in helix 3, the mutant protein is predicted to be transcriptionally inactive; either by inability or only partial ability to bind DNA. In addition, we postulate that the mutant CDX2 protein interferes with the ability of the wildtype CDX2 protein to bind DNA. The nature of this interference may involve direct interactions between mutant and wild-type CDX2, competition for essential cofactors for function, and/or competition for binding of the promoter site.
The dominant negative nature of the CDX2 mutant may confer it an oncoprotein activity. This may explain the discrepancy seen in Cdx2-null mice, which do not form adenocarcinomas (Beck et al., 1999; Tamai et al., 1999) . Cdx2 happloinsucient mice undergo reprogramming of their colon to the more proximal small intestine (which normally has lower Cdx2 expression) and form villi in their cecum (Beck et al., 1999) . Biallelic inactivation of Cdx2 leads to hamartomas resembling the stomach (which does not express Cdx2) (Tamai et al., 1999) . Interestingly, there is intercalary regeneration between the homozygous null colonic hamartomas and heterozygous villous colon, again suggesting that the dose and gradient of CDX2 is important (Beck et al., 1999; Silberg et al., 2000) . This is reminiscent of segment formation in Drosophila, in which dose and gradient determine phenotypes such as bristles. We propose that while a decrease in dose of CDX2 leads to reprogramming of the cell, its dominant negative mutation contributes to neoplasia. This hypothesis is supported by reports of mutated CDX2 in replication error-positive colorectal cancers (Wicking et al., 1998) .
